La Construcción social del espacio euromediterráneo : políticas europeas y tratamiento del islamismo en la información del medio prensa

El propósito central de este trabajo de investigación es analizar el tratamiento informativo del islamismo en los medios europeos y árabes, y determinar si éste contribuye a la construcción social del espacio euromediterráneo, según las recomendaciones dirigidas al sector mediático por las iniciativas de integración euromediterránea y, en particular, por el Proceso de Barcelona-Unión por el Mediterráneo y de la Alianza de Civilizaciones

Tratamiento domiciliario de gonartrosis con parches de microcorrientes

Objective: To outline the treatment by patches of microcurrent at home of patients with disabling knee osteoarthritis to perform their activities of daily life and work. Material and methods: We selected 80 patients in the surgical waiting list for total knee arthroplasty. 40 of whom received active patch and 40 inactive. All were given exercise protocol knee. The variables analyzed were: pain (VAS), joint balance, muscular balance and quality of life (SF-12). Patients were reviewed after two months of treatment. Variables were analyzed with SPSS 17.0 statistical program. Results: Statistically significant results were obtained (p <0.05) for decrease in mean pain according to VAS scale. No significant differences for other variables were found. Conclusions: Microcurrent therapy could be an alternative in the treatment of knee osteoarthritis pain, with no differences with the traditional treatment.

Influencia del tratamiento con análogos de prostaglandinas sobre el grosor foveal en pacientes hipertensos oculares o con glaucoma operados de cataratas

Objetivo: Valorar el efecto sobre el grosor foveal de retirar el tratamiento con análogos de las prostaglandinas previamente a la cirugía de cataratas en pacientes con glaucoma o hipertensión ocular. Material y métodos: Estudio prospectivo y aleatorizado. Se incluyeron 90 ojos de 80 pacientes. Grupo A: Suspendió el tratamiento una semana antes de la cirugía y grupo B: Mantuvo el tratamiento. Resultados: No se encontraron diferencias significativas en el grosor foveal en ambos grupos (p&0.05). Conclusiones: La interrupción del tratamiento con análogos de prostaglandinas previa a la cirugía no influye en cambios en el grosor foveal en estos pacientes. Efecte del tractament amb anàlegs de prostaglandines en el gruix foveal en pacients amb hipertensió ocular o glaucoma

Comparación de los resultados a largo plazo de cirugía y valvuloplastia percutánea para el tratamiento de la estenosis pulmonar aislada.

Se compararon en una población de 211 pacientes con estenosis pulmonar reparada el tratamiento quirúrgico y percutáneo, las complicaciones y reintervenciones a largo plazo y predictores de las mismas. Los pacientes del grupo quirúrgico se intervinieron de forma más precoz, presentaban una anatomía más compleja, más síntomas y peor perfil hemodinámico. El tiempo medio de seguimiento global fue de 22 ± 10,21 años y no se observaron diferencias significativas en cuanto a la necesidad de reintervención. La aparición de complicaciones no difirió entre los dos grupos. Una mayor edad en el momento de la cirugía, defectos congénitos asociados y síntomas prequirúrgicos fueron factores de riesgo para padecer complicaciones mayores. Por lo tanto, a pesar de que la evolución a largo plazo es globalmente buena, la aparición de complicaciones y la necesidad de reintervención a lo largo del seguimiento no es despreciable y sigue reportándose a pesar de la introducción de la valvuloplastia percutánea como tratamiento de primera línea.

Tratamiento farmacológico de la EPOC estable

Pharmacological treatment of patients with stable COPD should be individualised. Inhaled bronchodilators are the mainstay of pharmacological treatment for COPD. Long-acting medications (LABA or LAMA) are recommended over short-acting agents (SABA or SAMA). Short-acting bronchodilators are used on demand to rapidly control symptoms regardless of level of severity. Long-acting bronchodilators are used as maintenance therapy and are the mainstay of treatment in patients with permanent symptoms. Initial treatment for COPD is monotherapy with a long-acting bronchodilator. Clinical practice guidelines do not specify the best bronchodilator to use. The choice should be made on an individual basis, taking into account the patient’s preferences, response to treatment, its potential side effects and cost. When monotherapy fails to control symptoms, the first recommended step is to check medication adherence, inhaler technique and adequacy of inhalation device, and if these are correct but monotherapy is still insufficient, treatment should be intensified with combined inhaled therapies. Most clinical practice guidelines recommend the use of long-term therapy with LABA+inhaled corticosteroids in patients who experience frequent exacerbations and with FEV1 <50%. Long-term monotherapy with inhaled corticosteroids or oral corticosteroids is not recommended, and neither is the regular use of mucolytics nor the use of roflumilast.

Freedom Trial First-Year Extension: Results from 4 Years of Denosumab Exposure in Women with Postmenopausal Osteoporosis

Aims: To investigate the long-term efficacy and safety of denosumab (DMAb) for the treatment of postmenopausal women with osteoporosis in an open-label extension to the 3-year FREEDOM study.1Methods: All women who completed the FREEDOM study were eligible to enter a long-term open-label extension (up to 10 years). After providing informed consent, participants received 6-monthly subcutaneous injections of DMAb (60 mg). Here we report data from the first year of followup. For women randomized to DMAb in the FREEDOM study ('long-term group'), this represents up to 48 months of DMAb exposure (eight 6-monthly injections). For those randomized to placebo ('de novo group') the data are from up to 12 months of exposure (two injections). All participants continued to take calcium (1 g) and vitamin D (≥400 IU) supplements daily. Changes in bone mineral density (BMD) and bone turnover markers (BTM) are reported for subjects enrolled in the extension. No formal statistical testing was planned for this interim report. P-values are descriptive.Results: Overall, 4,550 eligible women (70.2%) who completed the FREEDOM study entered the open-label extension study (long-term, n=2,343; de novo, n=2,207). During the first year of the extension, lumbar spine (LS) BMD in the long-term group further increased by 2.0% (12.1% increase vs. FREEDOM baseline at 48 months), and total hip (TH) BMD further increased by 0.8% (6.5% increase at 48 months) (p<0.0001 for both BMD gains during year 4; Fig. 1). During the first year of the extension, LS and TH BMD increased by 5.4% and 3.0%, respectively in the de novo group (both p<0.0001). After DMAb initiation, serum C-telopeptide (CTX) in the de novo group decreased rapidly and similarly to the long-term group (Fig. 2). Reductions in BTMs continue to attenuate at the end of the dosing interval as previously reported. Adverse event (AE) rates were similar (70.4% of women in the longterm group and 67.9% in the de novo group). Serious Aes were also similar (9.8% and 11.2% of women, respectively). During year 4, osteoporotic nonvertebral fractures were reported in 31 women in the long-term group and 51 in the denovo group.Fig. 1. Percentage change in BMD with denosumab for4 years (long-term) or 1 year (de novo)Fig. 2. Percentage change in sCTX over timeConclusions: These interim results suggest that continuation of DMAb treatment through 48 months is associated with further significant increases in spine and hip BMD with sustained reduction of bone turnover. The de-novo treatment group results confirm the first year active treatment findings previously reported1.Acknowledgements: Amgen Inc. sponsored this study. Figure ©2010, American Society for Bone and Mineral Research, used by permission, all rights reserved. Disclosure of Interest: H. Bone Grant/Research Support from: Amgen, Eli Lilly, Merck, Nordic Bioscience, Novartis, Takeda Pharmaceuticals, Consultant/Speaker's bureau/ Advisory activities with: Amgen, Merck, Takeda Pharmaceuticals, Zelos, S. Papapoulos Consultant/Speaker's bureau/ Advisory activities with: Amgen, Merck, Novartis, Lilly, Procter and Gamble, GSK, M.-L. Brandi Grant/Research Support from: MSD, GSK, Nycomed, NPS, Amgen, J. Brown Grant/Research Support from: Abbott, Amgen, Bristol Myers Squibb, Eli Lilly, Pfizer, Roche, Consultant/ Speaker's bureau/Advisory activities with: Abbott, Amgen, Eli Lilly, Novartis, Merck, Warner Chilcott,, R. Chapurlat Grant/Research Support from: Servier, Sanofi-Aventis, Warner-Chilcott, Novartis, Merck, Consultant/Speaker's bureau/Advisory activities with: Servier, Novartis, Amgen, E. Czerwinski: None Declared, N. Daizadeh Employee of: Amgen Inc., Stock ownership or royalties of: Amgen Inc., A. Grauer Employee of: Amgen Inc., Stock ownership or royalties of: Amgen Inc., C. Haller Employee of: Amgen Inc., Stock ownership or royalties of: Amgen Inc., M.-A. Krieg: None Declared, C. Libanati Employee of: Amgen Inc., Stock ownership or royalties of: Amgen Inc., Z. Man Grant/Research Support from: Amgen, D. Mellström: None Declared, S. Radominski Grant/Research Support from: Amgen, Pfizer, Roche, BMS, J.-Y. Reginster Grant/Research Support from: Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier, Consultant/Speaker's bureau/ Advisory activities with: Servier, Novartis, Negma, Lilly,Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, Merck, Sharpe & Dohme, Rottapharm, IBSA, Genvrier, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Novo-Nordisk, H. Resch: None Declared, J. A. Román Grant/Research Support from: Roche, Pharma, C. Roux Grant/Research Support from: Amgen, MSD, Novartis, Servier, Roche, Consultant/ Speaker's bureau/Advisory activities with: Amgen, MSD, Novartis, Servier, Roche, S. Cummings Grant/ Research Support from: Amgen, Lilly, Consultant/Speaker's bureau/Advisory activities with: Amgen, Lilly, Novartis, Merck

Osteoporosis e índice de masa corporal en el trasplantado renal.

INTRODUCTION: frequently after kidney transplantation there is an increase in weight with a resulting high percent of obesity in these recipients. This combined with a rapid loss of bone mass, a higher prevalence of osteoporosis and fractures is evident than in normal populations. OBJECTIVES: to explore the relationship between body mass index (BMI) and prevalence of osteoporosis in a population of renal transplant recipients. METHODS: prospective longitudinal study design. The study was conducted on 306 kidney transplant recipients. The relationship between weigh and body mass index with femoral and lumbar osteopenia and osteoporosis prevalence at the moment of transplant and at 12 months post was explored. RESULTS: there was a high prevalence of overweight (35.6%) and obese (14.1%) recipients after renal transplant and 1 year after (42.2% and 24.2% respectively). Significant differences were found(p = 0.049) between the weight at the time of transplant and the presence of osteopenia or osteoporosis at the lumbar level one year after, the highest weights were in recipients with osteoporosis. The mean BMI was higher (p = 0.028) in osteoporotic patients (26.59 kg/m2) than in patients with osteopenia (24.23 kg/m2). CONCLUSION: results seem to be consistent with recent studies in the general population showing excessive weight as a possible factor detrimental to the bone health.

El Sistema de tratamiento de la información en EUROPOL

En la lucha contra el crimen organizado transnacional, uno de los actores principales lo constituye la Oficina de Policía Europea (EUROPOL), en tanto que es la Agencia de Seguridad de la Unión Europea y gestiona la información policial relacionada con la forma más grave de delincuencia transnacional. La Agencia colabora estrechamente con los Estados miembros, facilitando el intercambio de información y lleva a cabo Análisis Operativos y Análisis Estratégicos. Por lo tanto el análisis de la información, o el análisis de inteligencia, es crucial para todas las operaciones efectuadas por EUROPOL La Agencia está dotada de un Sistema de Tratamiento de la Información, siendo la base electrónica en donde están almacenados, tratados y analizados los datos enviados por los Estados miembros o aportados por los funcionarios de EUROPOL. Este Sistema está constituido por un Sistema de Información de EUROPOL, por los Ficheros de Análisis de EUROPOL, así como por un Sistema de Índice, cada uno teniendo sus funciones específicas previstas en la Decisión EUROPOL

Fracture risk and zoledronic acid therapy in men with osteoporosis.

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

IVA in addition to BMD can change the osteoporosis management in 25% of clinical routine patients

Introduction Vertebral fracture is one of the major osteoporoticfractures which are unfortunately very often undetected. In addition,it is well known that prevalent vertebral fracture increases dramaticallythe risk of future additional fracture. Instant Vertebral Assessment(IVA) has been introduced in DXA device a couple of years ago toease the detection of such fracture when routine DXA are performed.To correctly use such tool, ISCD provided clinical recommendationon when and how to use it. The aim of our study was to evaluate theISCD guidelines in clinical routine patients and see how often itmay change of patient management.Methods During two months (March and April 2010), a medicalquestionnaire was systematically given to our clinical routine patientto check the validity of ISCD IVA recommendations in our population.In addition, all women had BMD measurement at AP spine,femur and 1/3 radius using a Discovery A System (Hologic, Waltham,USA). When appropriate, IVA measurement had been performedon the same DXA system and had been centrally evaluated by twotrained doctors for fracture status according to the semi-quantitativemethod of Genant. The reading had been performed when possiblebetween L5 and T4.Results Out of 210 women seen in the consultation, 109 (52 %)of them (mean age 68.2 ± 11.5 years) fulfilled the necessary criteriato have an IVA measurement. Out of these 109 women, 43 (incidence39.4 %) had osteoporosis at one of the three skeletal sitesand 31 (incidence 28.4 %) had at least one vertebral fracture. 14.7 %of women had both osteoporosis and at least one vertebral fractureclassifying them as "severe osteoporosis" while 46.8 % did not haveosteoporosis and no vertebral fracture. 24.8 % of the women hadosteoporosis but no vertebral fracture while 13.8 % of women didhave osteoporosis but vertebral fracture (clinical osteoporosis).Conclusions In 52 % of our patients, IVA was needed accordingto ISCD criteria. In half of them the IVA test influenced of patientmanagement either may changing the type of treatment of simplyby classifying patient as "clinical osteoporosis". IVA appears to bean important tool in clinical routine but unfortunately is not yetvery often use in most of the centers.

Diagnóstico Radiológico y Resultados del Tratamiento Intraarterial en el Ictus del Despertar

En el presente trabajo se realiza una revisión del diagnóstico de la entidad clínica conocida como “ictus del despertar” y de los criterios de selección de los pacientes que pueden beneficiarse del tratamiento endovascular, que constituye una innovación en esta patología. También se valoran sus resultados inmediatos y a medio plazo, siguiendo la evolución clínica de los pacientes. Nos basaremos en una serie de 32 pacientes tratados en nuestro centro, el Hospital Universitari de Bellvitge, desde octubre de 2010 y hasta marzo de 2012. A todos se les realizó anamnesis, exploración neurológica, TC craneal simple, angio-TC y TC perfusión. Se seleccionó a los candidatos a tratamiento con trombectomía mecánica intraarterial. A todos los pacientes se les realizó TC de control 24 horas después del inicio de los síntomas o de la realización de tratamiento. Se siguió la evolución clínica, calculando el NIHSS al finalizar el procedimiento y al alta, y a los tres meses se obtuvo la puntuación en la escala de Rankin. En esta presentación del ictus, es especialmente complejo determinar la existencia de parénquima cerebral salvable o "penumbra isquémica"; su presencia, determina la indicación del tratamiento. El TC perfusión se ha revelado como la herramienta más útil en esta criba. El tratamiento, correctamente indicado, es efectivo y mejora la calidad de vida de estos pacientes.

Estudio caso-control de las cefalosporinas como tratamiento empírico de la peritonitis bacteriana espontánea en los receptores de trasplante hepático ortotópico. Epidemiología e impacto en la mortalidad

La peritonitis bacteriana espontánea consiste en la infección del líquido ascítico en ausencia de un foco evidente intraabdominal. Los microorganismos causales más frecuentes son bacilos Gram negativos y cocos Gram positivos. Son escasos los datos en los pacientes trasplantados hepáticos que evolucionan a cirrosis. Se diseñó un estudio caso-control con el objetivo de determinar la idoneidad del tratamiento empírico con ceftriaxona en dicha población. No se observaron diferencias etiológicas entre ambos grupos y la sensibilidad a cefalosporinas de tercera generación fue similar. Los trasplantados presentaron mayor incidencia de insuficiencia renal, y mayor mortalidad durante el episodio y a 6 meses.

Estudio genetico de la osteoporosis: heredabilidad de las propiedades densitométricas, estructurales y de resistencia ósea y distribución fenotípica familiar.

La base genética de la osteoporosis primaria es compleja. Involucra a múltiples genes y factores ambientales que actúan de manera conjunta para determinar el riesgo. Actualmente disponemos de exploraciones genómicas, como el estudio de miRNA, que facilitan la identificación de los determinantes genéticos de las enfermedades poligénicas complejas. Presentamos un estudio prospectivo realizado en familias con genealogia extensa para estudiar e identificar la heredabilidad de las propiedades densitométricas, estructurales y de resistencia ósea con el fin de profundizar en el conocimiento de las bases genéticas de la osteoporosis.

Adherencia al tratamiento de la psoriasis en pacientes españoles.

El objetivo fundamental del estudio fue valorar el cumplimiento terapéutico en pacientes con psoriasis. A tal fin se realizó una encuesta online a pacientes que constaba de 75 preguntas. Según la información aportada por los 679 encuestados, el cumplimiento fue del 15,17%. El cumplimiento no mostró relación con la intensidad de la psoriasis ni con la afectación psicológica o de la calidad de vida. Sin embargo, el cumplimiento fue menor en los pacientes que seguían tratamiento tópico y mayor en los que seguían tratamiento sistémico. El cumplimiento también fue mayor en el grupo de pacientes que eran visitados con mayor frecuencia.

Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis.

Hajdu-Cheney syndrome is a rare autosomal dominant skeletal disorder with facial anomalies, osteoporosis and acro-osteolysis. We sequenced the exomes of six unrelated individuals with this syndrome and identified heterozygous nonsense and frameshift mutations in NOTCH2 in five of them. All mutations cluster to the last coding exon of the gene, suggesting that the mutant mRNA products escape nonsense-mediated decay and that the resulting truncated NOTCH2 proteins act in a gain-of-function manner.